FY2029 Earnings Forecast for MNPR Issued By HC Wainwright

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share estimates for Monopar Therapeutics in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst S. Lee forecasts that the company will post earnings of $3.66 per share for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share.

Other equities research analysts have also recently issued reports about the company. Piper Sandler assumed coverage on Monopar Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $72.00 price target on the stock. Rodman & Renshaw assumed coverage on Monopar Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $50.00 price target on the stock.

Monopar Therapeutics Stock Up 5.4 %

Shares of MNPR stock opened at $41.46 on Thursday. The stock has a market cap of $252.91 million, a price-to-earnings ratio of -21.05 and a beta of 1.23. The business’s fifty day moving average is $24.19 and its 200 day moving average is $12.34. Monopar Therapeutics has a twelve month low of $1.54 and a twelve month high of $41.94.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.09.

Insider Transactions at Monopar Therapeutics

In related news, CFO Karthik Radhakrishnan bought 1,550 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were purchased at an average cost of $16.25 per share, with a total value of $25,187.50. Following the completion of the purchase, the chief financial officer now owns 1,550 shares in the company, valued at approximately $25,187.50. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 34.90% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.